Treatment Clinical Trials for Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 73

  • Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has spread to 5 or fewer places in the body and involves 3 or fewer organs (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • IBI308 in Subjects With Advanced / Metastatic Solid Malignancies

    The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced / metastatic solid malignancies. Patients will be recruited for 2 cohorts: Cohort 1: Approximately 60 subjects with advanced / metastatic cancer and high tumor mutational burden (TMB); Cohort 2: 20 subjects with advanced / metastatic endometrial cancer (EC).
    Location: 2 locations

  • Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

    This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
    Location: 2 locations

  • PF-06821497 Treatment Of Relapsed / Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed / Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
    Location: 3 locations

  • Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

    Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating deacetylase inhibiting molecule) that, in preclinical studies, has been shown to simultaneously improve access to the DNA strands within cancer cells, break them and block damage repair. This Phase 1 / 2 study will enroll patients with various advanced solid tumors.
    Location: 3 locations

  • Nivolumab and Lutetium Lu 177-DOTA-TATE in Treating Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer or Grade I-II Lung Neuroendocrine Tumors That Are Advanced or Cannot Be Removed by Surgery

    This partially randomized phase I / II trial studies the best dose of lutetium Lu 177-tetra-azacyclododecanetetra-acetic acid (DOTA)-Tyr3-octreotate (TATE) when given together with nivolumab and to see how well they work in treating patients with extensive-stage small cell lung cancer that has come back or does not respond to treatment or grade I-II lung neuroendocrine tumors that have spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as nivolmuab, may interfere with the ability of tumor cells to grow and spread. Radioactive drugs, such as lutetium Lu 177-DOTA-TATE, may carry radiation directly to tumor cells and not harm normal cells. Giving nivolumab and lutetium Lu 177-DOTA-TATE may work better in treating patients with small cell lung cancer or long neuroendocrine tumors.
    Location: 7 locations

  • FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

    This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: - Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. - Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. - Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
    Location: 2 locations

  • A Study of ABBV-181 in Participants With Advanced Solid Tumors

    This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine. The study will consist of 2 parts: ABBV-181 monotherapy dose escalation and expansion, and ABBV-181 in combination with Rovalpituzumab Tesirine.
    Location: 2 locations

  • A Phase I / II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

    The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7, 8 and 9) and MEDI4736 in combination with olaparib and bevacizumab (module 6 and 10). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
    Location: 2 locations

  • Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors

    Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.
    Location: 2 locations

  • Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
    Location: 2 locations

  • Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer

    This randomized phase II trial studies how well cisplatin or carboplatin and etoposide with or without vandetanib works in treating patients with previously untreated extensive stage small cell lung cancer or high-grade or poorly differentiated neuroendocrine cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cisplatin or carboplatin and etoposide is more effective with or without vandetanib in treating small cell lung cancer or neuroendocrine cancer.
    Location: 2 locations

  • Nivolumab and Temozolomide in Treating Patients with Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

    This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

    This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III LD-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

    This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Talazoparib and Low-Dose Temozolomide in Treating Participants with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

    This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating participants with extensive-stage small cell lung cancer than either one alone.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

    This is a multicenter, open-label, Phase 1 study of SC-011 given as a single agent and in combination with ABBV-181 in subjects with relapsed or refractory small cell lung cancer (SCLC). The study consists of 3 parts: Part A is a single-agent SC-011 dose-finding regimen cohort; followed by Part B, a single-agent SC-011 dose expansion cohort; and then Part C, an SC-011 and ABBV-181 combination escalation and expansion cohort.
    Location: 2 locations

  • Nivolumab and Vorolanib in Treating Participants with Non-Small Cell Lung Cancer and Refractory Thoracic Tumors

    This phase I / II trial studies the side effects and best does of vorolanib when given in combination with nivolumab in treating participants with non-small cell lung cancer and thoracic tumors that aren't responding to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and vorolanib may work better in treating participants with non-small cell lung cancer and thoracic tumors.
    Location: 4 locations

  • M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

    Background: Small cell lung cancer (SCLC) is an aggressive cancer. People with SCLC tend to be respond well to chemotherapy at first, but become resistant to treatment after a few months. Researchers want to see if combining two chemotherapy drugs with the drug M7824 will help the immune system fight tumors in people with SCLC. The chemotherapy drugs are topotecan and temolozomide. Objective: To determine the efficacy of M7824 plus topotecan or temozolomide in relapsed SCLC. Eligibility: Adults ages 18 and older diagnosed with SCLC whose disease has not responded to prior treatment Design: Participants will be screened with - Blood and urine tests - Medical history - Physical exam - Electrocardiogram to test heart function - Computed tomography and positron emission tomography scans Participants will be divided into three groups. Group A and Group B will get M7824 through a tube inserted in a vein for about 1 hour on Day 1 of a 21-day cycle. Group B will also get topotecan in a vein for about 30 minutes on Days 1 through 5 Group C will get M7824 for 1 hour on Days 1 and 15 of a 28-day cycle. They will also take temozolomide by mouth for 5 days each cycle. Group A will continue cycles as long as the disease responds to treatment. If it gets worse, they may be moved to Group B or C. During the study, participants will have physical exams and blood tests. They may have tumor samples taken. Participants will have a follow-up visit about 4 weeks after stopping the study drugs. They will have a physical exam and blood will be drawn.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline

    This phase I / II trial studies the best dose and side effects of stereotactic radiosurgery intreating participants whose cancer cells have spread to the brain from other organs in the body and studying their neurocognitive decline. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Stereotactic Radiosurgery followed by Tumor Treating Fields Therapy in Treating Participants with Small Cell Lung Cancer with Brain Metastases

    This trial studies how well stereotactic radiotherapy followed by tumor treating fields therapy work in treating participants with small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Given stereotactic radiosurgery and tumor treating fields therapy may help to reduce the chances of cancers coming back in other parts of your brain that are not being treated with stereotactic radiosurgery.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Ipilimumab, Nivolumab, and Ad.p53-DC in Treating Participants with Relapsed Small Cell Lung Cancer

    This phase II trial studies the side effects of ipilimumab, nivolumab, and Ad.p53-DC, and to see how well they work in treating participants with small cell lung cancer that has come back after previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Cancer vaccines, such as Ad.p53-DC, may help the body build an effective immune response to kill cancer cells by telling cells which targets to attack. Giving ipilimumab and nivolumab in combination with Ad.p53-DC, may kill more tumor cells in participants with relapsed small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

    A study to evaluate the safety and tolerability of AMG 119 in adult subjects with Relapsed / Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate cell dose.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of PLX2853 in Advanced Malignancies.

    The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York